Clinical trials: Digestive Tract Diseases
Cystic Fibrosis
Do Physiotherapy Techniques Improve Posture During Admission for a Chest Infection in Adults With Cystic Fibrosis?
Hypothesis: The addition of a series of musculoskeletal techniques to normal optimal care for the treatment of a respiratory exacerbation in inpatient adults with cystic fibrosis, will lead to further improvements in pain…
- Trial name
- NCT00806884
- Testing
- Physiotherapy Musculoskeletal Treatment, Control group measurements
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Cholelithiasis
Laparo-endoscopic Single Site (LESS) Cholecystectomy Versus Standard LAP-CHOLE
The aim of this study is to assess possible differences between the LESS approach and the standard laparoscopic approach to cholecystectomy.
- Trial name
- LESSCHO (NCT01339325)
- Testing
- Cholecystectomy
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- San Giovanni Addolorata Hospital
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 750 people
- Sponsor
- DualityBio Inc.
Insulin Resistance, Ethanol
The Effects of Ethanol on Intestinal Permeability and Gut Hormones
The aime of this study is to envsitigate if ethanol has an incretin effect. This is done by administration of ethanol orally vs. an isoethanolaemic i.v. infusion of ethanol.
- Conditions
- Insulin Resistance, Ethanol, Incretin Effect
- Trial name
- NCT03348371
- Testing
- Ethanol
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Healthy Volunteers
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40.
- Trial name
- ABBV-576 DDI (NCT05530278)
- Testing
- Galicaftor, ABBV-576, Navocaftor
- Where
- 4 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AbbVie
Cystic Fibrosis, Chronic Respiratory Failure
Effect of Non-Invasive Ventilation in Cystic Fibrosis Patient With Chronic Respiratory Failure.
There is no randomised controlled trials to determine the clinical effects of long term Non-Invasive Ventilation in Cystic Fibrosis patients.
- Trial name
- NCT00208078
- Testing
- pressure support ventilator
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Cochin Hospital
Cholangiocarcinoma, Adenocarcinoma of Gallbladder
A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC
The primary objective is to investigate the objective response rate in patients receiving GEMOX (gemcitabine plus oxaliplatin) plus cetuximab as first line treatment in advanced or metastatic unresectable BTC biliary tract cancer…
- Trial name
- BTC (NCT01267344)
- Testing
- gemcitabine, oxaliplatin, cetuximab, gemcitabine, oxaliplatin
- Where
- Taiwan
- Volunteers
- 122 people
- Sponsor
- National Health Research Institutes, Taiwan
Eosinophilic Esophagitis
Allergy Immunotherapy in the Management of Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) is a disease that has increased in incidence over the past decade that affects males predominantly, and in adults, is characterized by heartburn, dysphagia, strictures and food impactions.
- Trial name
- AIMEE (NCT01685034)
- Testing
- Allergy immunotherapy ("allergy shots")
- Sponsor
- United States Naval Medical Center, San Diego
Cystic Fibrosis
Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis
The proposed study is designed to characterize the pharmacokinetics of intravenous and oral tedizolid in patients with Cystic Fibrosis.
- Trial name
- NCT02444234
- Testing
- Tedizolid PO, Tedizolid IV
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Southern California
Obesity, Prediabetes
Effects of a GLP-1 Formula Drink on Gut Microbiota and Glycemic Control in Prediabetic Individuals
A clinical human dietary intervention trial was conducted to investigate the effects of GLP-1 FORMUL liquid supplementation in individuals with prediabetes or obesity, with a focus on improvements in glycemic and lipid…
- Trial name
- NCT07089732
- Testing
- GLP-1 formula liquid drink
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chung Shan Medical University
Biliary Tract Cancer
A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
This study is for patients with biliary tract cancer that has spread and who are not candidates for surgical resection. The purpose of this research is to determine if bevacizumab can be safely administered with Modified FOLFOX 6…
- Trial name
- NCT00881504
- Testing
- "Bevacizumab" in combination with "modified FOLFOX6".
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Georgetown University
Type 2 Diabetes Mellitus
Research on Changes in Intestinal Barrier Function and Gut Microbiome in Patients With Type 2 Diabetes After Duodenal Mucosal Resurfacing (DMR)
The aim of this study is to demonstrate the effects of duodenal mucosal resurfacing (DMR) on intestinal barrier function and gut microbiota when treating uncontrolled type 2 diabetes.
- Trial name
- DMR-IBF-GM (NCT06385704)
- Testing
- DMR Procedure
- Volunteers
- 100 people
- Sponsor
- Wang Siqi
Colon Cancer
NIMA-Colon Cancer Study
The goal of this study is to evaluate the effects of nutritional supplementation and physical activity interventions on recovery, muscle strength, nutritional status, inflammation, and metabolic health in adults with colon cancer…
- Trial name
- NIMA (NCT07534852)
- Testing
- Standard hypercaloric-hyperproteic nutritional supplementation, HMB-enriched hypercaloric-hyperproteic nutritional supplementation with vitamin D and calcium, Supervised exercise program
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Type 2 Diabetes
SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies
The aim of this study is to detail the (mechanisms underlying the) actions of the GLP-1 receptor agonists and DPP-4 inhibitors on the cardiovascular, renal and gastrointestinal systems in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01744236
- Testing
- Liraglutide, Sitagliptin, Exenatide
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Melanoma, Prostate Cancer
An Expanded Access Program for AM0010 (Pegilodecakin)
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- NCT03554434
- Testing
- AM0010
- Sponsor
- Eli Lilly and Company
Metabolic Diseases, Immune System Disorder
Study on the Effects of Wheat and Corn Germ Blend Oil on Antioxidation and Immune Regulation of Dyslipidemia Population
The goal of this clinical trial is to explore the role of wheat and corn germ blended oils in regulating oxidative stress and immunomodulation in dyslipidaemic populations, to explore their effects on intestinal flora…
- Conditions
- Metabolic Diseases, Immune System Disorder, Dyslipidemias, Fatty Acid Metabolism Disorder
- Trial name
- NCT06060509
- Testing
- Phytosterol-rich Wheat and Corn Germ Blended Oil, Peanut oil
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Southeast University, China
Cachexia, Gastrointestinal Cancer
Screening to Predict Weight Loss in Patients With Cancer
RATIONALE: Screening tests may identify people with cancer who are at high risk of losing weight and help doctors plan better treatment.
- Conditions
- Cachexia, Gastrointestinal Cancer, Hematopoietic/Lymphoid Cancer, Lung Cancer
- Trial name
- NCT00710632
- Testing
- laboratory biomarker analysis, physiologic testing, questionnaire administration
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Queen's Medical Center
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.